Physician profile
Robert Mohr
NPI 1750314480
$6,724.66
in general payments reported to CMS, 2019-2025
58 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $607 · 2021: $825 · 2022: $734 · 2023: $1,513 · 2024: $1,416 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,972.30 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.01 | 2019-2025 | |
| Amgen INC. | $856.47 | 2019-2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $630.66 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $590.42 | 2019-2022 | |
| Lilly USA, LLC | $454.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $431.57 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $252.05 | 2023-2025 | Rexulti |
| Abbott Laboratories | $198.51 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $173.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $151.75 | 2020-2024 | Spravato, Xarelto |
| Alkermes, INC. | $151.66 | 2019-2024 | Vivitrol, Vivitrol |
| Phathom Pharmaceuticals, INC. | $150.00 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.27 | 2019-2024 | Relistor, Trulance |
| Astrazeneca Pharmaceuticals Lp | $132.74 | 2020-2025 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.18 | 2025 | Caplyta |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.